CSF2 and temporal arteritis: Mavrilimumab impacts inflammatory pathways considered relevant to the pathogenesis of vascular inflammation and injury, and the results from a recent phase 2 trial in which mavrilimumab was superior to placebo (both with 26-week prednisone taper) in reducing the risk of GCA flare and maintaining sustained remission35 validated the role of GM-CSF in GCA.